Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?
Treatment of cancer has transformed with the introduction of checkpoint inhibitors. However, the majority of solid tumor patients do not respond to checkpoint blockade. In contrast, the response rate to programmed cell death 1 (PD-1) blockade in relapsed/refractory classical Hodgkin lymphoma (cHL) i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-12-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/1179554920976366 |
| _version_ | 1818643658442801152 |
|---|---|
| author | Ah-Reum Jeong Edward D Ball Aaron Michael Goodman |
| author_facet | Ah-Reum Jeong Edward D Ball Aaron Michael Goodman |
| author_sort | Ah-Reum Jeong |
| collection | DOAJ |
| description | Treatment of cancer has transformed with the introduction of checkpoint inhibitors. However, the majority of solid tumor patients do not respond to checkpoint blockade. In contrast, the response rate to programmed cell death 1 (PD-1) blockade in relapsed/refractory classical Hodgkin lymphoma (cHL) is 65% to 84% which is the highest among all cancers. Currently, checkpoint inhibitors are only approved for cHL and primary mediastinal B-cell lymphoma as the responses to single-agent checkpoint blockade in other hematologic malignancies is disappointingly low. Various established biomarkers such as programmed cell death 1 ligand 1 (PD-L1) protein surface expression, mismatch repair (MMR) status, and tumor mutational burden (TMB) are routinely used in clinical decision-making in solid tumors. In this review, we will explore these biomarkers in the context of hematologic malignancies. We review characteristic 9p24.1 structural alteration in cHL and primary mediastinal B-cell lymphoma (PMBCL) as a basis for response to PD-1 inhibition, as well as the role of antigen presentation pathways. We also explore the reported frequencies of MMR deficiency in various hematologic malignancies and investigate TMB as a predictive marker. |
| first_indexed | 2024-12-17T00:02:27Z |
| format | Article |
| id | doaj.art-f7e4710073fe41299144c2800e03a938 |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-17T00:02:27Z |
| publishDate | 2020-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-f7e4710073fe41299144c2800e03a9382022-12-21T22:11:03ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492020-12-011410.1177/1179554920976366Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?Ah-Reum Jeong0Edward D Ball1Aaron Michael Goodman2Division of Hematology and Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA, USADivision of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA, USADivision of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA, USATreatment of cancer has transformed with the introduction of checkpoint inhibitors. However, the majority of solid tumor patients do not respond to checkpoint blockade. In contrast, the response rate to programmed cell death 1 (PD-1) blockade in relapsed/refractory classical Hodgkin lymphoma (cHL) is 65% to 84% which is the highest among all cancers. Currently, checkpoint inhibitors are only approved for cHL and primary mediastinal B-cell lymphoma as the responses to single-agent checkpoint blockade in other hematologic malignancies is disappointingly low. Various established biomarkers such as programmed cell death 1 ligand 1 (PD-L1) protein surface expression, mismatch repair (MMR) status, and tumor mutational burden (TMB) are routinely used in clinical decision-making in solid tumors. In this review, we will explore these biomarkers in the context of hematologic malignancies. We review characteristic 9p24.1 structural alteration in cHL and primary mediastinal B-cell lymphoma (PMBCL) as a basis for response to PD-1 inhibition, as well as the role of antigen presentation pathways. We also explore the reported frequencies of MMR deficiency in various hematologic malignancies and investigate TMB as a predictive marker.https://doi.org/10.1177/1179554920976366 |
| spellingShingle | Ah-Reum Jeong Edward D Ball Aaron Michael Goodman Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Clinical Medicine Insights: Oncology |
| title | Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? |
| title_full | Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? |
| title_fullStr | Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? |
| title_full_unstemmed | Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? |
| title_short | Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? |
| title_sort | predicting responses to checkpoint inhibitors in lymphoma are we up to the standards of solid tumors |
| url | https://doi.org/10.1177/1179554920976366 |
| work_keys_str_mv | AT ahreumjeong predictingresponsestocheckpointinhibitorsinlymphomaareweuptothestandardsofsolidtumors AT edwarddball predictingresponsestocheckpointinhibitorsinlymphomaareweuptothestandardsofsolidtumors AT aaronmichaelgoodman predictingresponsestocheckpointinhibitorsinlymphomaareweuptothestandardsofsolidtumors |